Monkeys To Men: “Animal Rule” Study Of Cipro In Plague Gets Advisory Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
NIH studied the antibiotic known for its efficacy against anthrax as a treatment for pneumonic plague in African Green Monkeys because clinical trials cannot be conducted in human beings.
You may also be interested in...
Animal Rule Studies Should Be As Well-Designed As Human Clinical Trials, Panel Says
FDA's Anti-Infective Drugs Advisory Committee unanimously said ciprofloxacin and Ortho-McNeil-Janssen Pharmaceuticals Inc.’s Levaquin (levofloxacin) had proven their efficacy for pneumonic plague in studies in African Green Monkeys, but the panel may be less willing to overlook study design flaws in less life-threatening conditions.
Smallpox Treatments: Are Monkeypox Or Mousepox Acceptable Substitutes For Studying The Virus?
Smallpox has been eradicated for more than 30 years, but FDA isn't sure whether sponsors studying treatments in animals in case terrorists deliberately infected people can use substitute pathogens under the “Animal Rule.” The Antiviral Drugs Advisory Committee will weigh in on the issue.
CDER Mobilizes For Bioterrorism Threat: PDUFA Deadlines Safe, Center Says
User-fee deadlines will not be affected by FDA's efforts to respond to bioterrorism, Center for Drug Evaluation & Research Deputy Director Steven Galson, MD, told the Regulatory Affairs Professionals Society annual meeting Nov. 5 in Baltimore